Silexion Therapeutics Corp

About Silexion Therapeutics Corp

Silexion Therapeutics (Nasdaq: SLXN) is an oncology-focused biotechnology firm. In early 2026, the company is on track to initiate Phase 2/3 trials for its lead candidate, SIL204, in locally advanced pancreatic cancer (LAPC) across sites in Israel and Germany, targeting a $30+ billion global market.